Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

with aducanumab having a greater affinity for high molecular weight species, lecanemab targeting protofibrils over plaque, and donanemab targeting a modified form of beta amyloid called N3pG that ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading ... s already-approved Leqembi (lecanemab), which works in a similar ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they slowed the progression of memory-robbing illness in its early stages by up to 35 ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...

One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab ... amyloid antibody donanemab that, according ...